Trials / Completed
CompletedNCT02771379
Post Authorisation Safety Study With Raxone in LHON Patients
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 229 (actual)
- Sponsor
- Santhera Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idebenone | Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician. |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2021-04-16
- Completion
- 2021-04-16
- First posted
- 2016-05-13
- Last updated
- 2021-07-16
Locations
26 sites across 6 countries: Austria, France, Germany, Greece, Italy, Netherlands
Source: ClinicalTrials.gov record NCT02771379. Inclusion in this directory is not an endorsement.